Want to see RPID full AI Analyst Report?
Earnings Data
Report Date
Jul 31, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.27Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed but improving picture: revenue, product/consumables growth, recurring revenue expansion, system placements, and a strategic MilliporeSigma partnership are meaningful positives and support long-term margin improvement. However, near-term challenges include low absolute gross margins, a widened net loss, elevated operating expenses, significant Q1 cash burn, and variability in service revenue tied to validation timing. Management reiterated full-year revenue guidance and outlined margin improvement expectations, but execution risk and liquidity depend on achieving planned cost reductions, converting the sales funnel (including MilliporeSigma-driven placements), and unlocking credit facility tranches.Company Guidance
Revenue Growth
Total revenue of $8.0M in Q1 2026, up 11% year-over-year (from $7.2M). Full-year 2026 revenue guidance reaffirmed at $37M to $41M.
Strong Product and Consumables Performance
Product revenue rose 36% year-over-year to $5.6M (driven by systems and consumables). Consumables grew more than 30% and drove a record quarter for consumables.
Recurring Revenue Expansion
Recurring revenue increased 28% year-over-year to $5.1M and represented 63% of total revenue in Q1, showing greater revenue stability and higher attach-rate trends.
System Placement Momentum
Placed 6 Growth Direct systems in the quarter (vs. 3 in Q1 2025); 196 systems placed globally as of March 31, 2026, including 160 fully validated systems. Multisystem follow-on order from Samsung Biologics highlighted large-customer traction.
Margin Improvement Trajectory
Total Q1 gross margin was 5% (in line with guidance) and product margin improved materially to negative 8% from negative 23% a year ago (15 percentage-point improvement). Consumable margins improved ~33 percentage points due to material cost reductions and manufacturing productivity.
Strategic Partnership with MilliporeSigma
Expanded collaboration includes Rapid Micro as exclusive provider of validation, qualification and maintenance services for Growth Direct systems sold by MilliporeSigma; progressing toward supply agreement expected to improve consumable sourcing and margins and expand addressable markets (pharma, personal care, medical devices).
Geographic and Commercial Progress
First Growth Direct placed in China plus placements in Singapore and Australia; hosted Japan Growth Direct Day and planned North America Growth Direct Day (sponsored by Amgen) to accelerate customer adoption and reference-site building.
RPID Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RPID Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $2.48 | $2.32 | -6.45% |
Mar 12, 2026 | $4.38 | $3.42 | -21.80% |
Nov 07, 2025 | $2.75 | $3.10 | +12.73% |
Aug 12, 2025 | $3.26 | $2.68 | -17.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rapid Micro Biosystems (RPID) report earnings?
Rapid Micro Biosystems (RPID) is schdueled to report earning on Jul 31, 2026, After Close (Confirmed).
What is Rapid Micro Biosystems (RPID) earnings time?
Rapid Micro Biosystems (RPID) earnings time is at Jul 31, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RPID EPS forecast?
RPID EPS forecast for the fiscal quarter 2026 (Q2) is -0.24.